Myalgic Becker Muscular Dystrophy Due to an Exon 15 Point Mutation: Case Series and Literature Review
- PMID: 36409343
- DOI: 10.1097/CND.0000000000000413
Myalgic Becker Muscular Dystrophy Due to an Exon 15 Point Mutation: Case Series and Literature Review
Abstract
Dystrophinopathies result from mutations to the DMD gene. We report 5 boys in 3 families with heterogenous phenotypes due to a point mutation in the DMD gene: a hemizygous tyrosine-to-cysteine change in exon 15 (c.1724T>C) resulting in an amino acid substitution of leucine to proline at codon 575. This mutation has been reported before, with at least 3 prior patients presenting with similar clinical findings of myalgia, myoglobinuria, and occasional muscle cramping. The mutation on DMD c.1724T>C (p.Leu575Pro) is listed in the Clinvar database as a variant of unknown significance. Our report provides contributing evidence that this alteration should be classified as pathogenic.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors report no conflicts of interest.
Similar articles
-
[Mutation screening of 433 families with Duchenne/Becker muscular dystrophy].Zhonghua Yi Xue Za Zhi. 2016 Apr 26;96(16):1261-9. doi: 10.3760/cma.j.issn.0376-2491.2016.16.008. Zhonghua Yi Xue Za Zhi. 2016. PMID: 27122458 Chinese.
-
Exon skipping induced by nonsense/frameshift mutations in DMD gene results in Becker muscular dystrophy.Hum Genet. 2020 Feb;139(2):247-255. doi: 10.1007/s00439-019-02107-4. Epub 2020 Jan 9. Hum Genet. 2020. PMID: 31919629 Free PMC article.
-
Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.Acta Myol. 2020 Dec 1;39(4):179-186. doi: 10.36185/2532-1900-020. eCollection 2020 Dec. Acta Myol. 2020. PMID: 33458572 Free PMC article.
-
[Mutation-specific treatments for Duchenne muscular dystrophy].Brain Nerve. 2009 Aug;61(8):915-22. Brain Nerve. 2009. PMID: 19697880 Review. Japanese.
-
Contributions of Japanese patients to development of antisense therapy for DMD.Brain Dev. 2016 Jan;38(1):4-9. doi: 10.1016/j.braindev.2015.05.014. Epub 2015 Jun 18. Brain Dev. 2016. PMID: 26094594 Review.
References
-
- Melis MA, Cau M, Muntoni F, et al. Elevation of serum creatine kinase as the only manifestation of an intragenic deletion of the dystrophin gene in three unrelated families. Eur J Paediatr Neurol. 1998;2:255–261.
-
- Morrone A, Zammarchi E, Scacheri PC, et al. Asymptomatic dystrophinopathy. Am J Med Genet. 1997;69:261–267.
-
- Forrest SM, Cross GS, Flint T, et al. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. Genomics. 1988;2:109–114.
-
- Yang YM, Yan K, Liu B, et al. Comprehensive genetic diagnosis of patients with Duchenne/Becker muscular dystrophy (DMD/BMD) and pathogenicity analysis of splice site variants in the DMD gene. J Zhejiang Univ Sci B. 2019;20:753–765.
-
- Angelini C, Fanin M, Pegoraro E, et al. Clinical-molecular correlation in 104 mild X-linked muscular dystrophy patients: characterization of sub-clinical phenotypes. Neuromuscul Disord. 1994;4:349–358.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources